Compound
D0264 | Etomoxir
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| FATTY ACID METABOLISM | 0.1 to 50 μM | 24hr | MCF-7 and T47D cells | quantifies the conversion of [9,10-3H(N)]-palmitic acid to 3H2O with diffusion | inhibition | Student’s two-tail t-test, where p < 0.05 | 273 | |
| MITOCHONDRIAL FATTY ACID BETA OXIDATION | decrease | 35 | ||||||
| MITOCHONDRIAL FATTY ACID BETA OXIDATION | 0.29/0.34 | human/rat | hepatocytes | Fatty acid oxidation (FAO) was determined by measuring 14CO2 release from 14C-labeled palmitate | inhibition | IC50 (μM) | 333 | |
| SYNTHESIS OF KETONE BODY | 2.76 | Wistar rat | hepatocytes | ketone bodies (KB = β-hydroxybutyrate + acetoacetate) were determined with a commercially available kit (Autokit 3-HB from Wako) | inhibition | IC50 (μM) | 333 | |
| OXIDATIVE STRESS | 5 μM | T cell | 257 | |||||
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| carnitine palmitoyltransferases I | inhibitor | 35 | ||||||
| Carnitine O-palmitoyltransferase 1, liver isoform, CPT1-L, EC 2.3.1.21 | 5 μM | T cell | 257 | |||||
| 124083-20-1 | 2-Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester, (2R)- | 3994AH |
| A11415 | AKOS028109213 | AS-56541 |
| BCP07911 | BDBM50237625 | BRD-K32405725-001-01-0 |
| C17H23ClO4 | CHEBI:95011 | CHEMBL2051959 |
| CS-0325 | ETOMOXIR | Ethyl (+)-(R)-2-(6-(p-chlorophenoxy)hexyl)glycidate |
| Etomoxir [INN] | FT-0668432 | GTPL9089 |
| HY-50202 | MSB3DD2XP6 | NCGC00378789-04 |
| Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester, (2R)- | Q27077245 | R-(+)-Etomoxir |
| Rac-Etomoxir Ethyl Ester | SCHEMBL49075 | UNII-MSB3DD2XP6 |
| W-5482 | ZINC1851171 | ethyl (2R)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate |